Dr. Bhoj's genetics research aims to discover new human disease genes, their mechanisms, and potential targeted therapies. In addition to ongoing gene discovery efforts, Dr. Bhoj focuses on three novel genes that lead to pediatric neurologic dysfunction: TBC1 domain-containing kinase, Histone 3.3 (H3F3A and H3F3B), and MAP4K4.
Looking at a scientific problem from new and different perspectives is what research is all about, which is why Children's Hospital of Philadelphia's Research Institute is dedicated to cultivating a more diverse workforce. "We value diversity within our research community and it is undoubtedly part of what makes us successful," wrote Bryan A. Wolf, MD, PhD, Chief Scientific Officer and Director
The term “stem cell,” stammzellen, was first used in 1868 by the German biologist Ernst Haeckel to describe the original, unicellular progenitor from which Dr. Haekel supposed all multicellular plant and animal life might have descended.
First produced in the past decade, induced pluripotent stem cells — which are derived from adult cells — are capable of developing into many cell types. In two new studies, investigators from The Children’s Hospital of Philadelphia reprogrammed skin cells from patients with rare disorders into induced pluripotent stem cells (iPSCs), highlighting the great promise these cells hold.
The focus of the Chou Laboratory is to investigate the mechanisms of normal hematopoietic development, understand how these become disrupted in hematologic diseases, and create novel tools using induced pluripotent stem cells (iPSCs) to model blood diseases and improve treatment.